The shorter the time to the first relapse of prostate cancer and to doubling of prostate specific antigen (PSA) at relapse, the poorer the prognosis, say researchers.
In a study by S. Nakata and colleagues from the department of urology, Ashikaga Red Cross Hospital, Japan, 74 patients who had been treated for prostate cancer but subsequently relapsed were investigated. All had been treated with endocrine therapy, and all of their PSA values had declined to 10 ng/ml or lower during treatment.
In patients with more advanced prostate cancer, defined as clinical stage D, pre-treatment PSA was significantly higher than those with less advanced disease (stage B or C, p<0.01). Patients with more advanced cancer also had a shorter time period from the start of treatment to relapse (p<0.05). The time it took for PSA to double was also shorter for the advanced group (p<0.01).
e-Med Tools
קצר קולע וממוקד
e-Med סמינרים
אי-מד תחקירים
Medscape Tools
Journal Club
מרכזי מידע ושירות
Facebook
מידע למפרסם
מאגר תרופות
מאגר אנשי המקצוע
אינדקס שימושי
חדשות משה"ב
eMed HealthClub
מחקרים קליניים
השאירו תגובה
רוצה להצטרף לדיון?תרגישו חופשי לתרום!